Revolutionizing Drug Development

We are an emerging, oncology-focused, clinical stage pharma at the intersection of Artificial Intelligence, Genomics, and Machine Learning. Our mission is to deliver precision oncology therapies to the right cancer patients with significantly reduced costs and timelines.

Making Precision Cancer Therapy a Reality

We are an emerging, oncology-focused, clinical stage pharma at the intersection of Artificial Intelligence, Genomics, and Machine Learning. Our mission is to deliver precision oncology therapies to the right cancer patients with significantly reduced costs and timelines.

Vanquish, Defeat, Crush Cancer

We are an emerging, oncology-focused, clinical stage pharma at the intersection of Artificial Intelligence, Genomics, and Machine Learning. Our mission is to deliver precision oncology therapies to the right cancer patients with significantly reduced costs and timelines.

Oncology drug development today is a perfect environment for AI

Oncology drug development is time consuming, costly and high risk, with rates of a successful outcome (drug approval) being very low. This is a perfect problem area for the application of machine learning and Artificial Intelligence.

Research Led – The technology enables more efficient novel drug positioning, existing drug repositioning, and the rescue and repurposing of shelved therapeutic assets.

Results Oriented – Lantern is focused on personalizing cancer therapies for patients and potentially improving the outcome for the patient.

RADR™ is being continually improved by Lantern Pharma for the development of our drug portfolio and to pinpoint patient groups that can be best treated by our therapies and the therapies of our partners.

RADR™ Platform Architecture

Lantern Pharma’s solution is through the development of a process that accurately stratifies patient populations into responders and non-responders for a wide variety of oncology therapies to de-risk clinical trials, develop companion diagnostics and increase the potential for successful FDA approval with reduced costs.

International Business Times Reprint

RADR™ White Paper

Trusted Partners

Bringing breakthrough approaches that can potentially change the cost curve and risk involved in cancer therapy development requires an immense network of talented collaborators and partners. At Lantern Pharma we are constantly looking to involve ourselves with like minded companies, organizations and people.

Lantern Pharma, Inc. informs you that our website uses its own and third party cookies to improve our services and collect statistical information about your browsing. By clicking accept, we consider that you accept its use. For more information, or to know how to change the configuration, consult our Privacy Policy.
I Accept